Status:
COMPLETED
Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Primary Vascular Dysregulation
Eligibility:
All Genders
18-48 years
Phase:
NA
Brief Summary
It is already known that the local treatment with Alphagan eye drops (a drug commonly used by glaucoma patients) reduces ocular blood flow. In-vitro studies suggest that the vasoconstrictive effect of...
Detailed Description
The investigators would like to investigate the effect of Alphagan eye drops, Xalatan eye drops and their combination (both Alphagan and Xalatan) on corneal temperature in healthy subjects with and wi...
Eligibility Criteria
Inclusion
- healthy
- age 18-48 years
- normal findings on ophthalmological examination
Exclusion
- history of ocular or systemic disease
- chronic or current systemic or topical medication
- drug or alcohol abuse
- art. hypertension
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01201551
Start Date
June 1 2011
End Date
November 1 2013
Last Update
December 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Basel, Dept. of Ophthalmology
Basel, Switzerland, 4031